Ischaemic heart disease assessment by cardiovascular magnetic resonance imaging

Postgraduate Medical Journal

Volumn 86, Issue 1019, 2010, Pages 532-540

  Raj, Vimal ^a   Agrawal, S K ^a  

^a PAPWORTH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DOBUTAMINE; GADOLINIUM;

ACUTE HEART INFARCTION; CARDIAC NUCLEAR MAGNETIC RESONANCE IMAGING; CLINICAL ASSESSMENT; CONTRAST ENHANCEMENT; CORONARY ARTERY; HEART MUSCLE CONTRACTILITY; HEART MUSCLE PERFUSION; HEART VENTRICLE FUNCTION; HUMAN; ISCHEMIC HEART DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; REVIEW;

FEMALE; GREAT BRITAIN; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MYOCARDIAL ISCHEMIA; MYOCARDIUM;

EID: 77956923848     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/pgmj.2009.093856     Document Type: Review

References (58)

1. Allender S, Peto V, Scarborough P, et al. Coronary heart disease statistics 2007. 2007 edition.
2. Pennell DJ, Sechtem UP, Higgins CB, et al. Clinical indications for cardiovascular magnetic resonance (CMR): Consensus Panel report. Eur Heart J 2004;25:1940-65.
3. Atkinson D, Teresi L. Magnetic resonance angiography. Magn Reson Q 1994;10:149-72.
4. Finn JP, Edelman RR. Black-blood and segmented k-space magnetic resonance angiography. Magn Reson Imaging Clin N Am 1993;1:349-57.
5. Mehdi P-A, Fernando RG, Jeffrey JB, et al. Performing cardiac MR imaging: an overview. Magnetic resonance imaging clinics of North America 2003;11:1-18.
6. Jonathan WW, Igor K, Robert MJ. MRI for the Assessment of Myocardial Viability. Magnetic resonance imaging clinics of North America 2007;15:505-25.
7. Mahrholdt H, Klem I, Sechtem U. Cardiovascular MRI for detection of myocardial viability and ischaemia. Heart (British Cardiac Society) 2007 Date created: 2006/12/15/ Date completed 2007;93:122-9.
8. Schmidt A, Wu KC. MRI Assessment of Myocardial Viability. Seminars in Ultrasound, CT, and MRI 2006;27:11-19.
9. Wagner A, Mahrholdt H, Sechtem U, et al. MR imaging of myocardial perfusion and viability. Magnetic resonance imaging clinics of North America 2003;11:49-66.
10. Allman KC, Shaw LJ, Hachamovitch R, et al. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol 2002;39:1151-8.
11. Mock MB, Ringqvist I, Fisher LD, et al. Survival of medically treated patients in the coronary artery surgery study (CASS) registry. Circulation 1982;66:562-8.
12. Hammermeister KE, DeRouen TA, Dodge HT. Variables predictive of survival in patients with coronary disease. Selection by univariate and multivariate analyses from the clinical, electrocardiographic, exercise, arteriographic, and quantitative angiographic evaluations. Circulation 1979;59:421-30.
13. Leong-Poi H, Rim SJ, Le DE, et al. Perfusion versus function: the ischemic cascade in demand ischemia: implications of single-vessel versus multivessel stenosis. Circulation 2002;105:987-92.
14. Rackley CE, Russell RO Jr. Left ventricular function in acute and chronic coronary artery disease. Annu Rev Med 1975;26:105-20.
15. Emond M, Mock MB, Davis KB, et al. Long-term survival of medically treated patients in the Coronary Artery Surgery Study (CASS) Registry. Circulation 1994;90:2645-57.
16. Walsh TF, Hundley WG. Assessment of Ventricular Function with Cardiovascular Magnetic Resonance. Magnetic Resonance Imaging Clinics of North America 2007;15:487-504.
17. Bottini PB, Carr AA, Prisant LM, et al. Magnetic resonance imaging compared to echocardiography to assess left ventricular mass in the hypertensive patient. Am J Hypertens 1995;8:221-8.
18. Grothues F, Moon JC, Bellenger NG, et al. Interstudy reproducibility of right ventricular volumes, function, and mass with cardiovascular magnetic resonance. Am Heart J 2004;147:218-23.
19. Myerson SG, Bellenger NG, Pennell DJ. Assessment of left ventricular mass by cardiovascular magnetic resonance. Hypertension 2002;39:750-5.
20. Pattynama PM, Lamb HJ, van der Velde EA, et al. Left ventricular measurements with cine and spin-echo MR imaging: a study of reproducibility with variance component analysis. Radiology 1993;187:261-8.
21. Stratemeier EJ, Thompson R, Brady TJ, et al. Ejection fraction determination by MR imaging: comparison with left ventricular angiography. Radiology 1986;158:775-7.
22. McNamara MT, Higgins CB. Magnetic resonance imaging of chronic myocardial infarcts in man. AJR Am J Roentgenol 1986;146:315-20.
23. Perrone-Filardi P, Bacharach SL, Dilsizian V, et al. Regional left ventricular wall thickening. Relation to regional uptake of 18fluorodeoxyglucose and 201Tl in patients with chronic coronary artery disease and left ventricular dysfunction. Circulation 1992;86:1125-37.
24. Baer FM, Voth E, Schneider CA, et al. Comparison of low-dose dobutamine-gradient-echo magnetic resonance imaging and positron emission tomography with [18F]fluorodeoxyglucose in patients with chronic coronary artery disease. A functional and morphological approach to the detection of residual myocardial viability. Circulation 1995;91:1006-15.
25. Schinkel AF, Bax JJ, Poldermans D. Clinical assessment of myocardial hibernation. Heart 2005;91:111-17.
26. Cerqueira MD, Weissman NJ, Dilsizian V, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 2002;105:539-42.
27. Geleijnse ML, Fioretti PM, Roelandt JR. Methodology, feasibility, safety and diagnostic accuracy of dobutamine stress echocardiography. J Am Coll Cardiol 1997;30:595-606.
28. Masood S, Yang GZ, Pennell DJ, et al. Investigating intrinsic myocardial mechanics: the role of MR tagging, velocity phase mapping, and diffusion imaging. J Magn Reson Imaging 2000;12:873-83.
29. Rerkpattanapipat P, Mazur W, Link KM, et al. Assessment of cardiac function with MR imaging. Magnetic resonance imaging clinics of North America 2003;11:67-80.
30. Sechtem U, Sommerhoff BA, Markiewicz W, et al. Regional left ventricular wall thickening by magnetic resonance imaging: evaluation in normal persons and patients with global and regional dysfunction. Am J Cardiol 1987;59:145-51.
31. Underwood SR, Rees RS, Savage PE, et al. Assessment of regional left ventricular function by magnetic resonance. Br Heart J 1986;56:334-40.
32. Nagel E, Lorenz C, Baer F, et al. Stress cardiovascular magnetic resonance: consensus panel report. J Cardiovasc Magn Reson 2001;3:267-81.
33. Kuijpers D, Janssen CHC, van DPRM, et al. Dobutamine stress MRI Part I Safety and feasibility of dobutamine cardiovascular magnetic resonance in patients suspected of myocardial ischemia. Eur Radiol 2004;14:1823-8.
34. Strach K, Meyer C, Schild H, et al. Cardiac stress MR imaging with dobutamine. Eur Radiol 2006;16:2728-38.
35. Nagel E, Lehmkuhl HB, Bocksch W, et al. Noninvasive diagnosis of ischemia-induced wall motion abnormalities with the use of high-dose dobutamine stress MRI: comparison with dobutamine stress echocardiography. Circulation 1999;99:763-70.
36. Nagel E, Lehmkuhl HB, Klein C, et al. Influence of image quality on the diagnostic accuracy of dobutamine stress magnetic resonance imaging in comparison with dobutamine stress echocardiography for the noninvasive detection of myocardial ischemia. Z Kardiol 1999;88:622-30.
37. Prasad SK, Lyne J, Chai P, et al. Role of CMR in assessment of myocardial perfusion. Eur Radiol 2005;15(Suppl. 2):B42-7.
38. Schwitter J, Nanz D, Kneifel S, et al. Assessment of Myocardial Perfusion in Coronary Artery Disease by Magnetic Resonance: A Comparison With Positron Emission Tomography and Coronary Angiography. Circulation 2001;103:2230-5.
39. Al-Saadi N, Nagel E, Gross M, et al. Noninvasive detection of myocardial ischemia from perfusion reserve based on cardiovascular magnetic resonance. Circulation 2000;101:1379-83.
40. Panting JR, Gatehouse PD, Yang GZ, et al. Abnormal subendocardial perfusion in cardiac syndrome X detected by cardiovascular magnetic resonance imaging. N Engl J Med 2002;346:1948-53.
41. Pereira RS, Prato FS, Sykes J, et al. Assessment of myocardial viability using MRI during a constant infusion of Gd-DTPA: further studies at early and late periods of reperfusion. Magn Reson Med 1999;42:60-8.
42. Pereira RS, Prato FS, Wisenberg G, et al. The determination of myocardial viability using Gd-DTPA in a canine model of acute myocardial ischemia and reperfusion. Magn Reson Med 1996;36:684-93.
43. McNamara MT, Tscholakoff D, Revel D, et al. Differentiation of reversible and irreversible myocardial injury by MR imaging with and without gadolinium-DTPA. Radiology 1986;158:765-9.
44. Thomsen HS. Nephrogenic systemic fibrosis: A serious late adverse reaction to gadodiamide. Eur Radiol 2006;16:2619-21.
45. Cowper SE, Robin HS, Steinberg SM, et al. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000;356:1000-1.
46. Shellock FG, Spinazzi A. MRI safety update 2008: part 1, MRI contrast agents and nephrogenic systemic fibrosis. AJR Am J Roentgenol 2008;191:1129-39.
47. Wagner A, Mahrholdt H, Holly TA, et al. Contrast-enhanced MRI and routine single photon emission computed tomography (SPECT) perfusion imaging for detection of subendocardial myocardial infarcts: an imaging study. Lancet 2003;361:374-9.
48. Ramani K, Judd RM, Holly TA, et al. Contrast magnetic resonance imaging in the assessment of myocardial viability in patients with stable coronary artery disease and left ventricular dysfunction. Circulation 1998;98:2687-94.
49. Gerber BL, Garot J, Bluemke DA, et al. Accuracy of contrast-enhanced magnetic resonance imaging in predicting improvement of regional myocardial function in patients after acute myocardial infarction. Circulation 2002;106:1083-9.
50. Kim RJ, Wu E, Rafael A, et al. The use of contrast enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Eng J Med 2000;343:1445-53.
51. Mahrholdt H, Wagner A, Holly TA, et al. Reproducibility of Chronic Infarct Size Measurement by Contrast-Enhanced Magnetic Resonance Imaging. Circulation 2002; 106:2322-7.
52. Kitagawa K, Sakuma H, Hirano T, et al. Acute myocardial infarction: myocardial viability assessment in patients early thereafter comparison of contrast-enhanced MR imaging with resting (201)Tl SPECT. Single photon emission computed tomography. Radiology 2003;226:138-44.
53. Klein C, Nekolla SG, Bengel FM, et al. Assessment of Myocardial Viability With Contrast-Enhanced Magnetic Resonance Imaging: Comparison With Positron Emission Tomography 10.1161/hc0202.102123. Circulation 2002;105:162-7.
54. Kuhl HP, Beek AM, van der Weerdt AP, et al. Myocardial viability in chronic ischemic heart disease: comparison of contrast-enhanced magnetic resonance imaging with (18)F-fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol 2003;41:1341-8.
55. McConnell MV, Ganz P, Selwyn AP, et al. Identification of anomalous coronary arteries and their anatomic course by magnetic resonance coronary angiography. Circulation 1995;92:3158-62.
56. Post JC, van Rossum AC, Bronzwaer JG, et al. Magnetic resonance angiography of anomalous coronary arteries. A new gold standard for delineating the proximal course? Circulation 1995;92:3163-71.
57. Kim WY, Danias PG, Stuber M, et al. Coronary magnetic resonance angiography for the detection of coronary stenoses. N Engl J Med 2001;345:1863-9.
58. Nijveldt R, Beek AM, Hirsch A, et al. 'No-reflow' after acute myocardial infarction: direct visualisation of microvascular obstruction by gadolinium-enhanced CMR. Neth Heart J 2008;16:179-81.